Login / Signup

High PD-L2 Predicts Early Recurrence of ER-Positive Breast Cancer.

Inna ChervonevaAmy R PeckYunguang SunMisung YiSameer S UdhaneJohn F LangenheimMelanie A GirondoJulie M JornsLubna N ChaudharySailaja KamarajuCarmen BergomMichael J FlisterJeffrey A HookeAlbert J KovatichCraig D ShriverHai HuJuan P PalazzoMarluce BibboTerry HyslopMarja T NevalainenRichard G PestellSerge Y FuchsEdith P MitchellHallgeir Rui
Published in: JCO precision oncology (2023)
Up to one third of treatment-naive ER+ breast tumors expressed high PD-L2 levels, which independently predicted poor clinical outcome, with evidence of further elevated risk of progression in patients who received adjuvant chemotherapy. Collectively, these data warrant studies to gain a deeper understanding of PD-L2 in the progression of ER+ breast cancer and may provide rationale for immune checkpoint blockade for this patient group.
Keyphrases
  • positive breast cancer
  • endoplasmic reticulum
  • estrogen receptor
  • breast cancer cells
  • case report
  • electronic health record
  • clinical trial
  • hiv infected
  • big data
  • machine learning
  • antiretroviral therapy